On the HCPLive Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.
July 3rd 2024
Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.
UK Gives OK to Daklinza for Genotype 3 Hepatitis C Treatment
October 29th 2015The British health agency in charge of approving costs for drugs has given the thumbs up to Bristol-Myers Squibb to market its hepatitis C drug to include an indication for patients with genotype 3, reversing its recommendation from earlier this year.
Q&A with AbbVie's Barry Bernstein, MD: Are More FDA Warnings in the Works?
AbbVie's hepatitis C antivirals now come with a warning. In a Q&A with MD Magazine, Barry Bernstein, MD, the company's vice president for infectious disease product development, discusses the ramifications. It's not just AbbVie, he says, more post-market reports on other companies drugs are likely coming.
Cornell Studies Hepatitis C Populations Not Typically Tallied in Survey
October 26th 2015New research highlights how government estimates on hepatitis C prevalence in the United States leave out about 1 million people from several groups not regularly included in the tally, say researchers from Cornell University.
Study Looks at Clearance of Acute Hepatitis C in Cohort of Men
October 19th 2015Among men who have sex with men and became acutely infected with hepatitis C, the virus spontaneously cleared in nearly half the cases with higher percentages among men who were noninjection drug users than men who inject drugs, according to a prospective study out of Johns Hopkins University.
Patients with Hepatitis C Virus Often Do Not Know They Are Infected
More than three-quarters of intravenous drug users and Baby Boomers tested for hepatitis C were positive and unaware they were infected, according to results of a study published in the journal Annals of Emergency Medicine.
Can Non-Invasive Tests Assess Fibrosis in Hepatitis?
Percutaneous liver biopsy is a proven way to rate the fibrosis stage both in hepatitis in chronic hepatitis C patients and hepatitis B patients. But it is uncomfortable for patients, risks complications and is prone to assembling errors. Reporting at ID Week 2015 in San Diego, CA, Tuma Demirdal, DR, and colleagues at the Katip Celebi University in Izmir, Turkey compared these invasive tests with non-invasive methods.
Treating 5 Percent of All Patients with Hepatitis C Would Reduce Costs and Total Infections
October 8th 2015Comparing current treatment models to lessons learned in the early days of the AIDs epidemic, University of Southern California researchers are advocating that more than just the sickest patients with hepatitis C be treated with new drugs that have much higher cure rates than past regimens.
New Hepatitis C Combination Shows Stellar Results Across All Genotypes
Gilead continues a string of recent successes with stellar data from four late-stage studies showing that a combination featuring its blockbuster polymerase inhibitor sofosbuvir (Sovaldi®) and the experimental NS5A inhibitor velpatasvir is effective across all hepatitis C virus (HCV) genotypes.
HCV Reinfection Rates Increasing in HIV-Positive Men
September 29th 2015Researchers report high reinfection rates and attributable risk analysis suggest the existence of a subset of HIV-positive men who have sex with men with recurring sexual exposure to hepatitis C virus, which is troubling because HCV infections are more likely to become persistent and to lead to progressive liver disease in patients with HIV, including those on antiretroviral therapy.
Despite Cost, Medicaid Programs Spending Heavily on Hep C Drug
Expensive and worth it. That's the verdict from Medicaid programs across the US when it comes to the new hepatitis C antivirals. State spending figures are available in a study published as a letter in the New England Journal of Medicine.
Study Shows Increase in Hepatitis C Rate Among Some HIV-Positive Men
September 18th 2015Researchers conducted an analysis of studies that spanned more than two decades and found that outbreaks of sexually transmitted hepatitis C is increasing among men who are HIV positive and have sex with other men.
Hepatitis C Virus Enzyme Could Provide Novel Drug Target
September 18th 2015Scientists in Italy say they have gained new insight into how the hepatitis C virus replicates as a result of studying the behavior of a key enzyme and creating a computer model that shows how it interacts with the viral genome.
State Governments Responding to Curative but Costly Hepatitis C Medications
Several states – including Delaware and Georgia – are beginning to take action to increase diagnosis and access to treatment for patients with hepatitis C. The news comes in the wake of several studies showing that patients are often denied treatment. In addition, a highly regarded health council recently asked the White House to remove the restrictions that Medicaid often places on costly treatments that effectively amount to a cure for the potentially deadly disease.
Health Experts to White House: "Widen Access to Hepatitis C Medications"
Experts from the Public Health Service and President Obama's Advisory Council on HIV/AIDS have asked the administration in a letter to widen access to new, high-cost medications that successfully treat hepatitis C.